Therapeutic Efficacy of Astatine-211–Labeled Trastuzumab on Radioresistant SKOV-3 Tumors in Nude Mice Stig Palm, Ph.D., Tom Bäck, Ingela Claesson, Anna Danielsson, Ph.D., Jörgen Elgqvist, Ph.D., Sofia Frost, M.Sc., Ragnar Hultborn, M.D., Ph.D., Holger Jensen, Ph.D., Sture Lindegren, Ph.D., Lars Jacobsson, Ph.D. International Journal of Radiation Oncology • Biology • Physics Volume 69, Issue 2, Pages 572-579 (October 2007) DOI: 10.1016/j.ijrobp.2007.06.023 Copyright © 2007 Elsevier Inc. Terms and Conditions
Fig. 1 Percentage of injected activity per gram (%IA/g) for intraperitoneally injected astatine-211 (211At)-trastuzumab (∼400 kBq on ∼5 μg monoclonal antibody [mAb]) in organs at 1.3, 3.5, 9, and 19 h (n = 5 for each time point) after injection. Values corrected for radioactive decay and presented as the mean ± standard error of mean (standard error of mean is one standard deviation of mean). ∗Activity concentration in thyroid determined from throat specimens (see “Methods and Materials” section). International Journal of Radiation Oncology • Biology • Physics 2007 69, 572-579DOI: (10.1016/j.ijrobp.2007.06.023) Copyright © 2007 Elsevier Inc. Terms and Conditions